<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095146</url>
  </required_header>
  <id_info>
    <org_study_id>K-PAE-10-284</org_study_id>
    <nct_id>NCT01095146</nct_id>
  </id_info>
  <brief_title>New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome</brief_title>
  <acronym>MAS-D</acronym>
  <official_title>Comparison of Predictive Ability of New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amrita Institute of Medical Sciences &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amrita Institute of Medical Sciences &amp; Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Macrophage activation syndrome(MAS) is a complication of bone marrow suppression,
      coagulopathy and CNS dysfunction which occurs in rheumatic diseases. Normally the
      (Hemophagocytic Lympho-Histiocytosis) HLH-2004 criteria is used to diagnose patients with
      MAS. However this criteria is probably not sensitive and would probably be fulfilled quite
      late into the disease. Thus there would be an unacceptable delay. Ravelli et al came up with
      a different set of criteria based on data of patients reported in literature.

      Systemic onset juvenile idiopathic arthritis (SoJIA) is the most common cause of MAS. MAS in
      other rheumatic illnesses occurs in the setting on unbridled inflammation. In both SoJIA and
      uncontrolled rheumatic disease the patient is liable to have high WBC counts and high
      platelet counts. Bone marrow suppression which is one of the pathognomic features of MAS
      would be picked up very late if absolute cut off values were utilized. Kelly et al used the
      same arguments in their review to suggest that in MAS/Reactive hemophagocytic
      lymphohistiocytosis(ReHLH), the trend of change in laboratory parameters would be more useful
      than absolute cut offs. Hence the investigators propose new candidate criteria which are
      based on trends of laboratory parameters and seek to determine their utility in comparison to
      absolute cut offs of HLH or Ravelli criteria. The investigators also wanted to determine that
      among the Ravelli criteria and HLH-2004 criteria, which were fulfilled earlier in patients
      diagnosed as having MAS.

      Study hypothesis:-Criteria which measure serial trend of laboratory parameters would be
      fulfilled earlier than absolute cut offs when diagnosing MAS in patients with rheumatic
      illness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abbreviations:- ANC:- Absolute neutrophil count DIC:- Disseminated intra-vascular coagulation
      HLH:- Hemophagocytic lymphohistocytosis IAHS:- Infection associated hemophagocytic syndrome
      MAS:- Macrophage activation syndrome MODS:- Multi-organ dysfunction syndrome NK cell:-
      Natural Killer cells ReHLH:- reactive HLH SoJIA:- Systemic onset juvenile idiopathic
      arthritis SLE:- Systemic lupu erythematosus WBC:- white blood cell count

      Background and Introduction:- The first appearance in literature of description of patients
      with what was later to be known as macrophage activation syndrome (MAS) is probably the
      description of SoJIA patients who had a fulminant course with hepatic failure by Boone et al1
      and those with coagulopathy by Silverman et al2. However the term &quot;macrophage activation
      syndrome&quot; (and Syndromes of inappropriate macrophage activation in childhood) was first used
      in medical literature by French pediatricians and hemat-oncologists3-5. The credit for the
      same is wrongly attributed to Stephen et al, who were actually the first to use the term in
      &quot;rheumatology&quot; literature in their description of 4 SoJIA patients with this complication6.
      It is evident from the quoted literature that MAS at the time of it's intial recognition as a
      symptom complex or complication of rheumatic illness, was a universally fatal illness. Since
      then our understanding of it's pathology and it's treatment has grown considerably.

      The main defect in MAS is deficient NK cell activity. Hence a trigger which stimulates the
      immune system leads to unchecked CD8+ T cell proliferation which persists even after
      elimination of the trigger. These T cells secrete IFN-gamma which leads to macrophage
      overstimulation. This in turn activates a cytokine storm production (TNF a, IL 1 and IL 6)
      and phagocytosis of marrow elements by the marcophages, ultimately leading to MODS7. MAS
      usually occurs in the setting of an untreated or inadequately controlled rheumatic disease
      with severe systemic inflammation. The diagnosis is difficult particularly against this
      background and therefore a high clinical suspicion is paramount.

      Among the many rheumatic diseases MAS has been predominantly described associated with SoJIA.
      The next most common rheumatic illness described has been SLE. The hallmarks of this
      complication are Bone marrow suppression, DIC with abnormal bleeding, encephalopathy/
      seizures, and hepatitis. MAS has been increasing been recognized to have similarities with
      Class II histiocytic disorders or hemophagocytic lymphohistiocytosis (HLH). In the most
      recent classification of these disorders Class II disorders have been further subdivided into
      primary (due to a genetic defect), secondary (due to infections, malignancies,
      immunodeficiency) and reactive (due to rheumatic diseases)8. The last category alludes to
      MAS.

      Rationale and justification:-The HLH disorders are diagnosed using the HLH criteria. However
      as pointed out by Kelly et al9 and Ravelli et al10 use of this criteria to diagnose patients
      with MAS (i.e. Reactive HLH) would lead to a unacceptable loss of sensitivity and significant
      delay. Some components of the HLH criteria such as Soluble NK cell activity, CD-25 values
      above normal for age, and molecular diagnosis consistent with HLH are neither practical nor
      feasible in most clinical settings for a majority of rheumatology patients.

      Ravelli et al came up with a different set of criteria for patients with MAS based on data of
      patients reported in literature10. A comparison of the 2 criteria in a retrospective
      longitudinal study11 (albeit with a very small sample size) showed that the Ravelli et al
      criteria to be much more sensitive and enabled patients to be diagnosed much earlier than
      when the HLH-2004 criteria was used. In both SoJIA and uncontrolled rheumatic disease the
      patient is liable to have high WBC counts and high platelet counts. Bone marrow suppression
      which is one of the pathognomic features of MAS would be picked up very late if absolute cut
      off values were utilized. Kelly et al used the same arguments in their review to suggest that
      in MAS/ReHLH, the trend of change in laboratory parameters would be more useful than absolute
      cut offs.

      Hence we propose new candidate criteria which are based on trends of laboratory parameters
      which would probably be able to predict MAS earlier than absolute cut offs of laboratory
      parameters.MAS has now undergone a name change (to Reactive HLH) and an image change (from an
      universally terminal illness to a dreaded but treatable complication). Hence the need for
      recognition and early diagnosis is more important today than ever before. In this era of
      potent and novel immuno-modulatory medications, a sensitive criteria which would pick up
      patients prone to develop MAS or in the process of developing MAS would give us the edge to
      finally help us rein in this terrifying disease.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Macrophage Activation Syndrome</condition>
  <condition>Lymphohistiocytosis, Hemophagocytic</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted in the Pediatrics, Internal Medicine, Rheumatology/Clinical Immunology
        departments of hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All the patients diagnosed as having Macrophage Activation Syndrome at death or
             discharge from 1st Jan 2004 to 1st Jan 2012, in all the centers enrolled as
             collaborators of the study would be included in the study

        Exclusion Criteria:

          -  Subjects with a final diagnosis of (Infection associated hemophagocytic syndrome) IAHS

          -  Subjects with a genetic diagnosis of HLH

          -  Subjects with a family history (1st degree relative) of a genetic diagnosis of HLH.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharath Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amrita Institute of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Kelly A, Ramanan AV. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol. 2007 Sep;19(5):477-81. Review.</citation>
    <PMID>17762614</PMID>
  </reference>
  <reference>
    <citation>Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, Viola S, Martini A. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005 May;146(5):598-604. Review.</citation>
    <PMID>15870661</PMID>
  </reference>
  <reference>
    <citation>Henter JI, Horne A, Aric√≥ M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31.</citation>
    <PMID>16937360</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>March 29, 2010</last_update_submitted>
  <last_update_submitted_qc>March 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sharath Kumar</name_title>
    <organization>Amrita Institute of Medical Sciences &amp; Research Center</organization>
  </responsible_party>
  <keyword>MAS</keyword>
  <keyword>Hemophagocytosis</keyword>
  <keyword>Reactive HLH</keyword>
  <keyword>Macrophage activation syndrome</keyword>
  <keyword>Systemic onset juvenile idiopathic arthritis</keyword>
  <keyword>SoJIA</keyword>
  <keyword>JIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Macrophage Activation Syndrome</mesh_term>
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

